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Abstract
Background: The goal of this study was to provide
reference ranges for thyrotropin (TSH) and free thy-
roxine (fT4) based on data collected from a disease-
free sample of French middle-aged adults.
Methods: A total of 3218 subjects participating in the
Supple´mentation en Vitamines et Mine´raux Antioxy-
dants (SU.VI.MAX) study had measurements for TSH,
fT4 and urinary iodine concentrations. Thyroid volume
and structure were evaluated using standardized
ultrasonography. We selected a disease-free sample
which included 2338 subjects (1313 females aged
35–60 years and 1025 males aged 45–60 years) with
normal thyroid imaging, no previously reported thy-
roid disease or use of thyroid medication, and no risk
factors for thyroid dysfunction. Distribution of TSH
and fT4 was estimated in males and females.
Results: The median (central 95% range) TSH serum
concentrations for females were 1.79 mU/L
(0.29–5.21 mU/L) for ages 35–44 years and 1.98 mU/L
(0.27–6.94 mU/L) for ages 45–60 years (p-0.0001, for
age). The median (central 95% range) for males
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45–60-year-old was 1.63 mU/L (0.28–4.54 mU/L) (p-
0.0001, for sex). Sex- and age-specific mean fT4 con-
centrations did not differ significantly (ps0.06)
between males and females and (ps0.08) between
female age groups. However, median fT4 concentra-
tions between 45–60-year-old males and females dif-
fered (p-0.001).
Conclusions: In middle-aged adults, the TSH distri-
bution was associated with gender and, among
females, with age. Stratification according to gender
and age should be considered when TSH ranges are
used in the diagnosis, treatment and monitoring of
thyroid disease.
Clin Chem Lab Med 2009;47:1497–505.
Keywords: adults; free thyroxin; ranges; thyrotropin;
ultrasonography.
Introduction
Epidemiological studies using biochemical thyroid
function tests and/or clinical investigation have
shown the prevalence of thyroid disorders to be about
10% in iodine-replete populations, occurring more
frequently in females, and with aging in normal
subjects (1). Clinical and biochemical diagnosis and
follow-up, and the wide use of thyroid hormones yield
high public-health-related costs. For example, in
France, refunds for required hormonal thyroid func-
tion testing (10.2 million reimbursements) amounted
to 137 million Euros in 2006 (2). The annual prescrip-
tion volume for Levothyrox (levothyroxine sodium)
resulted in more than 18 million unit reimbursements
(3). Reliable reference ranges, defined using appar-
ently healthy individuals, must be established in order
to adequately diagnose and manage thyroid dysfunc-
tion in the general population.
Measurement of serum thyrotropin (TSH) is the
recommended initial screening tool for suspected
thyroid disease. Daytime reference values for TSH in
adults are in the range of 0.3–4.0 mU/L, with a mini-
mum between 0.2 and 0.5 mU/L and a maximum
between 3.0 and 5.0 mU/L (4). The prevalence of
endogenous subclinical thyroid disease varies with
the TSH cut-off used to define them. Subclinical
hyperthyroidism has been defined as a serum TSH
concentration of 0.10–0.44 mU/L (5), and subclinical
hypothyroidism as a serum TSH concentration of
4.5–10.0 mU/L (6). These criteria are sufficient when
using an assay with adequate sensitivity. However,
measurement of free thyroxine (fT4) might also be
recommended to confirm the diagnosis of subclinical
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hypothyroidism or hyperthyroidism, and to determine
diagnostic strategies (7). Typical reference intervals
for fT4 have usually been defined as 9–25 pmol/L
(7.0–19.4 ng/L) (4).
Various criteria exist for defining an apparently
healthy sample. Recent publications have used the
National Academy of Clinical Biochemistry (NACB)
consensus guidelines. These guidelines recommend
selecting a reference sample by excluding subjects
positive for autoantibodies against thyroid peroxidase
(TPOAbs) and thyroglobulin (TgAbs), with visible or
palpable goiter, and those taking any drugs except
estrogens (8). Exclusion of subjects with a personal or
family history of autoimmune disease, thyroid-related
or not, is also recommended. Such rigorous selection
would not lead to erroneous estimation of thyroid
dysfunction. Indeed, exclusion of subjects with
enlarged thyroid volume and diffuse hypoechogeni-
city of the thyroid on ultrasound examination could
lead to better selection of individuals in the reference
sample. Currently, there is no agreement concerning
age- and gender-specific differences with regard to
TSH and fT4 concentrations, despite reported varia-
tions (9–12). Diversity of current analytical methods
and the specificity and sensitivity of enzyme immu-
noassays, as well as interpopulation variability
(10–12), may explain the wide discrepancies between
published reference range data (13, 14). Investigating
and providing TSH reference values in various pop-
ulations are also of interest, given risk factor varia-
tions in populations for body mass index (BMI) (15),
alcohol intake (16), smoking habits (17) and iodine
intake (18).
The objective of the present study was to determine
serum TSH and fT4 ranges in French middle-aged
adults included in the Supple´mentation en Vitamines
et Mine´raux Antioxydants (SU.VI.MAX) study. These
individuals were determined to be free of thyroid
disease, with normal thyroid ultrasonography and not
taking medication that would interfere with thyroid
hormone testing.
Materials and methods
Study population (1994–2002)
The SU.VI.MAX study was a double-blind, placebo-
controlled primary prevention trial evaluating the effect of
daily antioxidant supplementation on the incidence of chron-
ic disease (19). A total of 13,017 subjects recruited on a vol-
untary basis following a multimedia campaign, and living in
mainland France, were included in 1994–1995 to be followed
for 8 years. Due to the main objective of the trial, more
female (60%) than male participants were included. Females
had a wider age range compared with males (35–60 years
vs. 45–60 years). Written informed consent was obtained
from all participants, and procedures were approved by the
Regional Ethics Committee of Paris-Cochin wComite´ consul-
tatif de protection des personnes dans la recherche biome´-
dicale (CCPPRB), n8706x and the French Data Protection
Authority wCommission National de l’Informatique et des
Liberte´s (CNIL), n8334641x.
Each subject underwent a yearly visit involving either bio-
chemical sampling (at years 0, 2, 5 and 7) or clinical exami-
nation (at years 1, 3 and 7). Social and demographic
characteristics were collected at inclusion by questionnaire.
These included smoking habits (never, former or current
smoker), marital status (whether subjects lived with a part-
ner or not), education level (-13, 13–14, G15 years), men-
opausal status and use of exogenous estrogens. Subjects
were classified into one of four categories according to their
self-reported occupation, or last occupation if they were
retired or unemployed. Alcohol intake was estimated in
grams of alcohol per day from a short validated semi-quan-
titative dietary questionnaire (20). Heavy alcohol intake was
defined as daily self-reported consumption ofG45 g ethanol/
day for males and G20 g for females (16).
Laboratory methods (1994–1995)
At baseline examination (October 1994–September 1995), a
venous blood sample and morning urine sample were
obtained from participants. Time of blood collection was
between 7.30 am and 11.00 am. Blood was left to clot at 48C
and then centrifuged. Serum was aliquoted and stored at
–258C until analysis. Serum TSH and fT4 were measured in
duplicate in random order with a MAGIA 8000 analyzer
according to the manufacturer’s instructions (Biotrol Diag-
nostic Company, Chennevie`res-le`s-Louvres, France). TSH
was measured using a one-step, two-site ultrasensitive
enzyme-linked immunosorbent assay (ELISA) that utilized
two monoclonal antibodies. The detection limit of the TSH
assay was 0.02 mU/L. The TSH standard 80/558 from the
World Health Organization (WHO) was used as a calibrator
for the TSH determination. fT4 was measured using a one-
step competitive immunoassay. The lower limit of fT4 detec-
tion was 2 ng/L (conversion factor to pmol/L: ng/L=1.3).
Reference ranges provided by the manufacturer were: TSH,
0.12–6.1 mU/L; fT4, 7–17 ng/L (9.0–21.9 pmol/L). Within- and
between-run coefficients of variation for TSH and fT4 were
-7.6% over a wide range of concentrations.
Urinary iodine concentration was measured in all partici-
pants in a random morning sample and urinary iodine con-
centrations were used as an index of iodine nutrition. The
urinary iodine, after fully automated wet acid digestion
(Technicon AutoAnalyzer II, Technicon Instruments Corpo-
ration, Tarrytown, NY, USA) was measured by means of a
highly sensitive spectrophotometric procedure based on the
Sandell–Kolthoff reaction. Urinary thiocyanate concentra-
tions were measured using the same urine sample with an
automated continuous-flow technique.
Thyroid ultrasonography (1995–1996)
Ultrasonography examination of the thyroid was performed
in a randomly selected subsample of 3621 subjects (2160
females and 1461 males) after stratifying on gender, age and
geographic location. Subjects were informed of ultrasonog-
raphy examination on arrival at the screening site for the first
biennial clinical examination. Examination was carried out in
a mobile unit equipped with a high-frequency 7.5 MHz linear
array transducer (Sonoline SI-400, Siemens, Erlangen,
Germany). Studies were performed and interpreted by the
same radiologist. Participants also answered a questionnaire
concerning previous or present thyroid disease (total, sub-
total thyroidectomy, lobectomy, nodules, goiter), previous or
current use of thyroid medication (radioiodine, thyroid hor-
mone supplementation, iodine-based or antithyroid drugs)
and medications known to have an effect on thyroid hor-
mone concentrations (glucocorticoids, interferons, dopa-
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mine agonists, antiepileptic agents), with the exception of
estrogens. Ultrasonographic examinations were performed
with the patient in a supine position and the neck hyperex-
tended. Thyroid volume was estimated using the formula:
volume of one lobe (mL)slength (cm)=width (cm)=depth
(cm)=0.479 (21). Total thyroid volume (mL) was obtained by
computing the volume of both lobes. Nodules and cystic are-
as were included in thyroid volume determination, whereas
the isthmus was not taken into account in volume calcula-
tions. This method has been proven to be very accurate (22).
Goiter was defined as an enlarged thyroid volume exceeding
25 mL in males and 18 mL in females (23). Nodules and cysts
included all focal abnormalities of the echo pattern that were
3 mm or more in diameter. Nodule frequency (1–3 nodules,
paucinodularity, multinodularity) and components (solid and
cystic) were classified qualitatively. Thyroid tissue density
(echogenicity) which was slightly homogeneously more
echoic than adjacent neck muscles was considered to be
normal.
Statistical analysis
Statistical analyses were performed using Statistical Analy-
sis System (SAS) software 8.2 (SAS Institute, Inc, Cary, NC,
USA). Data were stratified according to gender and age in
females (35–44 years and 45–60 years). The disease-free
population was selected by successively excluding subjects
with a family or personal history of thyroid disease (removal
of thyroid lesions, nodule, goiter), subjects taking thyroid
medication and those with risk factors for thyroid dysfunc-
tion: iodine contamination (urinary concentration G600
mg/L), thiocyanate overload (urinary concentration G50
mg/L) and pregnancy at the time of hormone analysis.
Serum TSH concentrations and log-transformed values
were not normally distributed. TSH ranges were defined as
the central 95% of the selected population comprising the
2.5th and 97.5th percentiles. Intervals for fT4 were defined as
the 2.5th–97.5th percentiles following the exclusion of sub-
jects with serum TSH outside the 2.5th–97.5th percentiles.
Mann-Whitney U and Student’s t-tests were used to assess
differences between groups when required.
Results
Characterization of the disease-free population
Among the initial 3621 participants with thyroid ultra-
sonography, 3218 (88.9%) had complete data for TSH,
fT4, urinary iodine and thiocyanate concentrations at
baseline. Thyroid nodule, hyper- or hypoechogenic
pattern, diffuse goiter and documented thyroid sur-
gical therapy were the most frequent causes for
exclusion in the reference population (Figure 1). Alto-
gether, 880 subjects, 241 males and 639 females, who
had at least one (previously known or unknown)
thyroid disorder were excluded.
Thus, the disease-free population consisted of 2338
subjects (72.7% of the initial sample): 1025 males
(81.0%) aged (mean"SD) 52.0"4.8 years, 571
females (75.1%) aged between 35 and 44 years with
a mean age of 40.5"2.8, and 742 females (62.2%)
aged between 45 and 60 years with a mean age of
50.9"4.4. Within each group, the social and demo-
graphic characteristics were comparable to those in
the initial sample (Table 1). In this sample, 82.4% of
males, 54.6% of females aged 35–44 years, and 65.4%
of females aged 45–60 years consumed alcoholic bev-
erages, with mean alcohol intakes of 25.7"19.2,
6.8"8.7 and 9.4"10.3 g, respectively. One-quarter of
the participants (26.5%) had 15 years or more of edu-
cation, and 14.2% of the subjects currently smoked.
Smoking was lower in the selected male group than
in the total population (ps0.07).
In the disease-free population, thyroid volume was
significantly higher in males than in females
(p-0.0001). The median and mean thyroid volume in
the disease-free subgroups was smaller than the thy-
roid volume in the total population, and the upper lim-
its for thyroid volume decreased sharply (Table 2).
The median urinary iodine concentration was
-100 mg/L in all groups: 65.6% of males, 63.2% of
35–44-year-old females and 62.7% of 45–60-year-old
females had urinary iodine concentrations -100
mg/L. They were similar to concentrations measured
in the initial sample (Table 2).
Concentration intervals for TSH and fT4
In the disease-free population, the median TSH
value (central 95% range) was 1.63 (0.28–4.54)
mU/L in 45–60-year-old males, 1.79 (0.29–5.21) mU/L
in 35–44-year-old females and 1.98 (0.27–6.94) mU/L
in 45–60-year-old females (Figure 2). Although the
2.5th percentile was comparable between the three
groups, TSH median values increased significantly
with age category in females (p-0.0001). The upper
limit of TSH was 5.21 mU/L in 35–44-year-old females,
and increased by 33.2% for the 45–60-year-old age
group. Median TSH concentrations were higher in
45–60-year-old females than in males (p-0.0001),
and the TSH upper limit for females aged 45–60 years
was 52.9% higher compared to males of the same age
group (Figure 2).
Approximately one-fifth (20.8%) of the males, one-
fourth (27.2%) of the younger females and one-third
(33.9%) of the older females in our population had
TSH values )2.5 mU/L (Table 2). The corresponding
percentages for TSH )4.5 mU/L were 2.8%, 5.4% and
7.7%, respectively. Frequencies were slightly higher
in female than in male subjects; in females, the per-
centages increased with age (p-0.0001 within gender
and age groups). The corresponding figures for TSH
-0.2 mU/L were 1.7%, 0.9% and 1.1%, respectively
(Table 2).
A decrease in variation around the median TSH was
observed between the initial sample and the disease-
free sample (Table 2). While the spreads of values for
TSH were 4.57, 5.62, and 7.65 mU/L for the total pop-
ulation, the corresponding spreads for the selected
groups were 4.54, 5.21, and 6.94 mU/L. The TSH
upper limits were slightly lower in the subsample
than in the total population (Table 2).
The fT4 range was estimated in 2224 subjects (975
males aged 45–60 years, 544 females aged
35–44 years and 705 females aged 45–60 years) with
TSH concentrations between the 2.5th and 97.5th
percentiles. The fT4 median value (central 95%
range) was 10.7 (7.85–13.60) ng/L for males, 11.0
1500 Estaquio et al.: TSH and fT4 ranges in adults with normal ultrasonography
Article in press - uncorrected proof
Figure 1 Selection of the disease-free sample (SU.VI.MAX Study 1994–1996).
(7.85–14.90) ng/L for females aged 35–44 years and
10.9 (8.20–13.65) ng/L for females aged 45–60 years
(Figure 3). The difference was statistically significant
between males aged 45–60 years and females
(p-0.001). The mean fT4 concentrations were com-
parable between females aged 45–60 years compared
with those aged 35–44 years (ps0.08) and between
males and females aged 45–60-year-old (ps0.06)
(Figure 3). The mean fT4 concentration was unchang-
ed between the initial sample and the disease free
sample (Table 2).
Discussion
In our study, ranges for TSH and fT4 were derived
from a disease-free sample of French middle-aged
adults. All participants had normal thyroid ultraso-
nography and strict exclusion criteria, with the excep-
tion of TPOAb measurements. The distribution of TSH
differed significantly between males and females
from the same age category, and in females accord-
ing to age group. Mean fT4 and range intervals, esti-
mated in subjects with TSH within the normal range,
were comparable across age groups in females.
However, there were differences between 45–60-year-
old males and females. In our study, exclusion of
at-risk individuals increased the lower bounds of the
95% TSH limit, but had no effect on the mean and
upper range fT4 concentrations in groups according
to gender and age. In addition, the prevalence of mild
hypothyroidism (TSH )4.5 mU/L) was approximately
three-fold more common in females than males,
consistent with earlier studies (11, 24).
Estaquio et al.: TSH and fT4 ranges in adults with normal ultrasonography 1501
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Figure 2 Serum TSH level (mUI/L) distribution by gender and age groups.
Figure 3 Serum fT4 level (ng/L) distribution by gender and age groups (after exclusion of participants with TSH outside the
2.5th and 97.5th percentiles (reference interval). Conversion factor to pmol/Lsng/L=1.3.
Most studies established one reference interval for
a population, as recommended by the NACB (8). With
our data, serum TSH concentrations were significant-
ly affected by both age and gender, as reported in
previous studies (10, 11, 13). With respect to age, con-
flicting data have been reported. A trend toward high-
er serum TSH concentrations in older females was in
agreement with the age related shift in the upper ref-
erence limits for serum TSH (14, 25). However, other
studies reported a decline with age for serum TSH
(10, 12, 26). With gender, there were clear signs of an
upward shift for both the mean and the upper 95%
limit of the TSH range in females compared with
males. Previous descriptions of benign thyroid dis-
eases in the SU.VI.MAX cohort (27, 28) confirmed that
the thyroid is exposed to a goiter effect due to iodine
deficiency. In our study, age related changes in TSH
concentrations may reflect physiological ageing of the
thyroid as well as the iodine supply.
A recent NACB report suggested lowering the TSH
upper limit reference value from 4.5 to 2.5 mU/L (8).
This suggestion raised a storm of controversy
(29–31). Despite the fact that examination of individ-
uals was not based on NACB guidelines, which was
not published when data were collected for our study,
our interval limits can be assumed to be correct for
middle-aged French adults. In fact, we found an upper
limit of ;4.0 mU/L; this value is close to the upper
limit determined in studies using NACB guidelines
(11, 14, 24, 26, 32–35).
A potential limiting factor of this study is that thy-
roid antibodies were not available. Therefore, some
individuals with occult thyroid dysfunction were
included in the calculated reference intervals (36). In
fact, autoimmune thyroid disease is very common in
this population (37), and individuals assumed to be
disease free may have been contaminated by earlier
occult autoimmune thyroid disease not detected by
ultrasonography. However, several recent studies of
thyroid-disease-free individuals found no significant
change in the TSH upper limit in patients with anti-
thyroid antibodies (14, 35, 38). In addition, thyroid
hypoechogenicity, a criterion used in our study, is
considered a reliable tool for identifying chronic auto-
immune disease (39). Also, it is considered to be an
early marker of hypothyroidism in apparently healthy
subjects (40).
Another potential limitation was the use of an older
TSH assay which was considered acceptable when
this study was initiated. Single biochemical measure-
ments did not allow us to account for intraindividual
variability (41). However, pre-analytical and analytical
sources of variation were minimized through strict
standard operating procedures.
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The SU.VI.MAX study provided a unique opportu-
nity to characterize abnormal thyroid function in two
subsets of the SU.VI.MAX cohort. An initial evaluation
of abnormal TSH values based on serum samples
from apparently healthy subjects has already been
published (42). As mentioned previously, since exam-
inations of individuals was not based on NACB
guidelines, we took the opportunity to focus on the
ultrasonography subsample to define TSH and fT4
ranges in a disease-free population.
The strengths of our study lie in the relatively large
number of well-defined subjects, and a selection
procedure which excluded important confounding
factors. In addition, clinical or biological thyroid dys-
function was not included in the initial exclusion cri-
teria for participation in the SU.VI.MAX trial (19),
making selection bias very unlikely. In addition, ultra-
sonographic thyroid examinations were performed
on a random subsample of the SU.VI.MAX cohort
prior to completion of TSH and fT4 assays. Although
not a criterion in the NACB recommendations for
defining a healthy population (8), thyroid ultrasono-
graphy may be an important parameter since TSH
standards differed according to whether ultrasono-
graphy was or was not taken into consideration (12, 14).
Decreasing the reference limits would classify three
to four times more subjects as having hypothyroidism
(29, 34). In our population, decreasing the upper limit
of the TSH interval would dramatically increase (by
up to 26%) the diagnosis of biochemical hypothyroid-
ism. This would lead to supplementary medical
expenses; already high in France (2, 3). In addition,
decreasing the TSH upper limit of the reference range
from 4.5 to 2.5 mU/L (8) would result in potentially
unnecessary levothyroxine replacement therapy for
many patients for whom there is no demonstrated
therapeutic benefit (29). Further studies should deter-
mine whether variations due to gender, and to age in
females, are clinically relevant in order to validate the
advantage of using separate reference values.
Several studies have provided evidence that TSH in
the upper reference range is often associated with
primary cardiovascular risk factors in susceptible
individuals (43). Early treatment would prevent pro-
gression to subnormal values, but the balance
between benefits and harm is unclear. Large random-
ized trial studies are required to evaluate the potential
benefit of thyroid hormone therapy for metabolic
parameters and quality of life.
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